Pediatric Drug Development
Pediatric drug development addresses the unique pharmacological, ethical, and regulatory challenges of testing medicines in children.
## Why Pediatric Drug Development Is Different
Children are not small adults. Their bodies absorb, distribute, metabolize, and eliminate drugs differently at each developmental stage. Neonates have immature hepatic enzymes and renal function. Adolescents may metabolize certain drugs faster than adults. Diseases manifest differently in children, and drug responses can vary significantly by age. Despite this, over 50% of drugs prescribed to children have never been formally studied in pediatric populations.
## Age Categories
Regulatory agencies define pediatric subgroups with distinct pharmacological characteristics:
- **Preterm neonates**: < 37 weeks gestational age
- **Term neonates**: 0-27 days
- **Infants and toddlers**: 28 days to 23 months
- **Children**: 2-11 years
- **Adolescents**: 12-17 years (FDA) or 12-18 years (EMA)
Each subgroup may require separate studies because pharmacokinetic parameters, disease manifestation, and safety profiles differ across developmental stages.
## Regulatory Requirements
### Pediatric Research Equity Act (PREA)
PREA requires that all new drug and biologic applications include pediatric studies for relevant indications unless the sponsor obtains a waiver or deferral. This legislation ensures that drugs used in children are properly studied rather than prescribed off-label based on adult data alone.
### Best Pharmaceuticals for Children Act (BPCA)
BPCA provides a voluntary incentive: six months of additional marketing exclusivity in exchange for completing FDA-requested pediatric studies. This incentive applies to both patented and generic drugs.
### EU Pediatric Regulation
The EMA requires a Pediatric Investigation Plan (PIP) at the time of marketing authorization application. PIPs define the studies, formulations, and timelines for pediatric development. Compliance grants a six-month patent extension (SPC extension).
## Formulation Challenges
Children cannot swallow standard adult tablets. Age-appropriate formulations include oral liquids, dispersible tablets, mini-tablets, sprinkle capsules, and orally disintegrating films. Palatability is critical -- a medicine that tastes unacceptable will not be taken. Excipient safety is also a concern: preservatives and solvents acceptable in adults (e.g., benzyl alcohol, propylene glycol) can be toxic in neonates.
## Ethical Considerations
Pediatric trials require parental informed consent plus the child's assent (for children old enough to understand). The risk-benefit threshold is higher: trials must present a prospect of direct benefit or, for non-beneficial research, only minimal risk. Placebo use in children requires particularly rigorous ethical justification.
## Extrapolation and Modeling
When the disease mechanism and drug response are similar between adults and children, regulators accept pharmacokinetic extrapolation -- using adult efficacy data combined with pediatric PK studies to establish dosing without repeating full efficacy trials. Population PK modeling and physiologically based pharmacokinetic (PBPK) modeling increasingly support this approach.
## Key Takeaways
- Children metabolize drugs differently at each developmental stage
- PREA mandates pediatric studies for new drugs; BPCA provides exclusivity incentives
- Age-appropriate formulations and palatability are essential for adherence
- Ethical standards for pediatric trials require higher scrutiny than adult trials
- PK extrapolation from adult data can reduce the need for large pediatric efficacy trials